Physician profile
Stuart Samuel Burstein
NPI 1366522930
$1,825.18
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.44 · 2021: $25.47 · 2022: $705 · 2023: $908 · 2024: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.86 | 2022-2024 | Vraylar |
| Lundbeck LLC | $300.25 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $172.54 | 2022-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $168.95 | 2022-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $151.92 | 2022-2023 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.65 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $105.91 | 2022-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $103.47 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $83.22 | 2022-2023 | Hetlioz |
| Almatica Pharma LLC | $68.04 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $34.22 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $24.45 | 2023 | Auvelity |
| Tris Pharma INC | $22.66 | 2022 | |
| Bausch Health US, LLC | $22.38 | 2023 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $18.74 | 2023 | Trintellix |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $14.92 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Burstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.